Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETON-2: Inhaled treprostinil in idiopathic pulmonary fibrosis
2021-005881-17Phase 3Active
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Inhaled treprostinil with Placebo (2 arms). Primary endpoint: Change in absolute forced vital capacity. Started Jul 2022; status: active.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2021-005881-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005881-17.